FOSPHENYTOIN PRESCRIBING INFORMATION PDF

This resource may include information that has not been approved by the US Food and Drug Administration. For full prescribing information, including. Fosphenytoin official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. Medscape – Epilepsy dosing for Cerebyx (fosphenytoin), frequency-based adverse contraindications, pregnancy & lactation schedules, and cost information. be expressed as phenytoin sodium equivalents (PE) when prescribing; There is.

Author: Arakora Shabar
Country: Finland
Language: English (Spanish)
Genre: Video
Published (Last): 19 March 2013
Pages: 165
PDF File Size: 19.46 Mb
ePub File Size: 5.31 Mb
ISBN: 592-4-27725-595-6
Downloads: 7987
Price: Free* [*Free Regsitration Required]
Uploader: Neramar

Imidafenacin The metabolism of Fosphenytoin can be decreased when combined with Imidafenacin. Phenytoin fosphenyoin highly bound to prescrkbing proteins, primarily albumin, although to a lesser extent than fosphenytoin. Atenolol The metabolism of Atenolol can be increased when combined with Fosphenytoin.

Irreversible cerebellar dysfunction and atrophy have been reported after overdosage. FDA alerts for all medications. Metamfetamine The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Methamphetamine.

Medetomidine The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Medetomidine. Ketazolam The metabolism of Fosphenytoin can be decreased when combined with Ketazolam. Estramustine The metabolism of Fosphenytoin can be decreased when combined with Estramustine. For the control of generalized convulsive status epilepticus and prevention and treatment of seizures occurring during neurosurgery.

Fidaxomicin The metabolism of Fosphenytoin can be decreased when combined with Fidaxomicin. Buprenorphine Fosphenytoin may increase the central nervous system depressant CNS depressant activities of Buprenorphine. Women planning to become pregnant and in pregnant women In women planning to become pregnant all efforts should be made to switch to appropriate alternative treatment prior to conception, if possible.

This has the potential to increase the frequency and severity of adverse events. Pro-Epanutin is a prodrug intended for parenteral administration; its active metabolite is phenytoin. Delamanid The metabolism of Fosphenytoin can be decreased when combined with Delamanid. Captopril The metabolism of Captopril can be increased when combined with Fosphenytoin.

  JOHN RENBOURN FOLK BLUES AND BEYOND PDF

Mylan Worldwide

Inhibition of phenytoin metabolism may produce significant increases in plasma prescribinng concentrations and increase the risk of phenytoin toxicity.

Phenytoin the active metabolite of CEREBYX prenatal exposure may increase risks for congenital malformations and other adverse developmental outcomes 5. Chlorprothixene The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fosphenytoin. Inflrmation of the risks of cardiac and local toxicity associated with IV Fosphenytoin Sodium Injection, oral phenytoin should be used whenever possible.

Floxuridine The metabolism of Fosphenytoin can be decreased when combined prescrihing Floxuridine. Trough levels provide information about clinically effective serum level range and are obtained just prior to the patient’s next scheduled dose. Chlorphenamine The serum concentration of Fosphenytoin can be increased when it is combined with Chlorphenamine.

Signs of acute toxicity in animals included ataxia, labored breathing, ptosis, and hypoactivity. The clearance prescgibing phenytoin the active metabolite of CEREBYX is decreased slightly in elderly patients and lower or less frequent dosing may be required [see Clinical Pharmacology Binding to plasma proteins is saturable with the result that the percent bound decreases as total Fosphenytoin concentrations increase.

FOSPHENYTOIN SODIUM Injection mg PE in 2ml Vial mg PE in 10 ml Vial | Mylan

Severe cardiac complications have been reported in elderly, children especially infantsor gravely ill patients following administration of fosphenytoin.

Fulvestrant The metabolism of Fosphenytoin can be decreased when combined with Fulvestrant. Antineoplastic agents usually in combination. It is therefore, important to eliminate prescribjng types of lymph node pathology before discontinuing therapy with Pro-Epanutin.

Posology Intravenous IV infusion: Hydroxyprogesterone The metabolism of Fosphenytoin can be decreased when combined with Hydroxyprogesterone. MK The risk or severity prescribin adverse effects can be increased when Fosphenytoin is combined with MK Deferiprone The metabolism of Deferiprone can be decreased when combined with Fosphenytoin.

Cathinone The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Cathinone. The pharmacokinetics and protein binding of Fosphenytoin, phenytoin, and diazepam were not altered when diazepam and Fosphenytoin Sodium Injection were concurrently administered in single submaximal doses.

  IEC 60317 PDF

Ganciclovir The therapeutic efficacy of Fosphenytoin can be decreased when used in combination with Ganciclovir.

Fosphenytoin – DrugBank

Cilnidipine The metabolism of Fosphenytoin can be decreased prescribinf combined with Cilnidipine. Cloprostenol The metabolism of Cloprostenol can be increased when combined with Fosphenytoin.

Eliglustat The metabolism of Eliglustat can be increased when combined with Fosphenytoin. Ajulemic acid The risk fosphenutoin severity of adverse effects can be increased when Ajulemic acid is combined with Fosphenytoin.

Ethynodiol diacetate The metabolism of Fosphenytoin can be decreased when combined with Ethynodiol diacetate. Date of revision of the text.

A meta-analysis of randomised, placebo controlled trials of anti-epileptic drugs has also shown a small increased risk of suicidal ideation and behaviour. Enflurane The risk or severity of adverse effects can be dosphenytoin when Enflurane is combined with Fosphenytoin. Rapid intravenous administration of Fosphenytoin Sodium Injection increases the risk of adverse cardiovascular reactions, including severe hypotension and cardiac arrhythmias.

Cabergoline The metabolism of Fosphenytoin can be decreased when combined with Cabergoline. Ambrisentan The metabolism of Fosphenytoin can be decreased when combined with Ambrisentan. When, in the judgment of the clinician, the need for dosage reduction, discontinuation, or substitution of alternative antiepileptic medication arises, this should be done gradually. Fosphenytoin displaces phenytoin from protein binding informatiom. Doxacurium The risk or severity of adverse effects can be increased when Doxacurium is combined with Fosphenytoin.

Barbital The metabolism of Fosphenytoin can be increased when combined with Barbital. Digitoxin The metabolism of Digitoxin can be increased when combined with Fosphenytoin. Coadministration with delavirdine because of the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.